is conducting research on Pfizer, a large global pharmaceutical company. He expects global nominal GDP to grow at 4.5% over the long run based on a 2% real growth rate and a 2.5% inflation rate. Bundini believes that global sales of Alzheimer's drugs will grow at a 100bp faster rate than nominal GDP over the long run and believes that sales of Pfizer's Alzheimer's drugs will decline from their current levels to the projected growth rate of the Alzheimer's drugs market over the next 5 years. Which of the following approaches to modeling Pfizer's revenues is Bundini most likely using? A) Top-down approach B) Bottom-up approach C) Hybrid approach